🔗 Share this article

As the US continues making unprecedented changes to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Program

Health officials planned to reveal radical changes to the childhood vaccine schedule recently, aligning the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US at odds with a large portion of the world with no evidence for benefit. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for ending specific pediatric immunization guidelines in the US in order to be more in line with the Danish model, a country with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent background in drug development, oversight or administrative roles, which has been customary for past directors of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Former heads of CBER would “understand regulatory frameworks and the research of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and all of those need to be looked after,” she noted. “The area you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major administrative element to the position, which supervises in excess of 5,000 personnel. “It is a enormous management job, if you do it right,” she concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among agency officials on vaccines, a representative responded that the “questions are based on flawed assumptions”.

“This background matches the responsibilities of her role,” the official stated, pointing to the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial one-day drug-approval program that allegedly concerned her preceding directors. “How are these therapies being picked for this fast-track system? Who makes the choices?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, aside from vaccines.”

Documented Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, past, critics said. She released a study using unconfirmed volunteer-provided data to assess the rate of myocarditis after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government included altering guidelines for novel immunizations and ending “non-essential” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who begins with her beliefs and works backwards to fit the data in a very disingenuous, fraudulent way,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of fellow dissenters, {like|